Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Date:10/20/2008

- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in First Stage of Trial Assessing Regimen of Bavituximab with Carboplatin and

Paclitaxel -

TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that it has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall tumor response rate in patients receiving the combination therapy.

Peregrine president and CEO Steven W. King noted, "The rapid completion of enrollment in the first stage of this study adds to the positive momentum we have built in our bavituximab clinical program. We look forward to reporting initial data from this trial as patient treatment and follow-up continue and to learning more about bavituximab's potential as a novel targeted therapy for this devastating disease."

In the trial's Simon two-stage design, 21 patients with NSCLC have been enrolled in Stage A of the study. The trial may be expanded to include up to a total of 49 patients if promising results are observed in the initial cohort. Secondary objectives of the study include assessing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients are receiving bavituximab and up to six cycles of carboplatin and paclitaxel, and they may continue to receive bavituximab as long as the cancer does not progress and side effects are acce
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., a ... in epilepsy and related neurological disorders, is today reporting ... lead compound INS001 in patients with drug-resistant epilepsy.  The ... Device Trials (AED) Xll meeting by Dr. ... Chairman of Insero,s Scientific Advisory Board.  In this study, ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... VAP Cholesterol test can help doctors and clinicians identify ... options for patients at risk of heart disease, ... a,new cholesterol-fighting drug combination point to the need for ... other,lipids. That,s according to Atherotech, a cardio-diagnostic company that,has ...
... ABAX ), a medical products company manufacturing point-of-care,blood ... its,financial results for the third quarter of fiscal year ... 4:15 p.m. ET, Thursday, January 31, 2008., Participants ... the,conference call, or can listen via a live Internet ...
... ARIUS, Product Candidate Trop-2 Signal ... Transduction Antibody ... a full-,service biopharmaceutical development and protein production company, today,announced that ... Research, Inc., a biotechnology company focused on discovering,and developing the ...
Cached Biology Technology:Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3
(Date:5/17/2013)... New Jersey, and City University of New York have ... that effectively clears organisms to be viewed under microscopes. ... which is one of the few high-quality clearing solutions ... Drug Enforcement Administration (DEA) due to its use as ... vital for viewing organisms under a microscope. Without them, ...
(Date:5/17/2013)... College study finds human-caused climate change may have ... contradicting a host of recent studies that predict ... , The findings, which appear in the journal ... for survival of a creature thought to be ... tropical cold-blooded animals, especially forest lizards, will be ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... 2012 Researchers from Seattle Biomedical Research Institute (Seattle BioMed), ... uncovered new knowledge related to host-parasite interaction in severe malaria, ... in the brain and cause cerebral malaria the most ... published in the May 21 online edition of PNAS ( ...
... Darwin, assembling an evolutionary tree that shows the relationships between ... grandest and most daunting challenges facing biologists. Despite 150 ... no single diagram that displays the links between all of ... and microorganisms. Now, with $5.76 million from the U.S. ...
... build a grand tree of life that brings together everything ... the tiniest bacteria to the tallest tree. Scientists ... ever since Charles Darwin drew the first sketches in his ... branches of the tree of life, today there is still ...
Cached Biology News:New discoveries about severe malaria 2U-M biologist plays key role in effort to create first comprehensive tree of life 2U-M biologist plays key role in effort to create first comprehensive tree of life 3Researchers aim to assemble the tree of life for all 2 million named species 2Researchers aim to assemble the tree of life for all 2 million named species 3
Chemically Defined Lipid Concentrate...
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Request Info...
Biology Products: